MedPath

Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery

Not Applicable
Completed
Conditions
Prostatic Neoplasm
Urinary Bladder Neoplasm
Interventions
Procedure: Fluid loading of volulyte 300 ml
Registration Number
NCT02977143
Lead Sponsor
Seoul National University Hospital
Brief Summary

In urologic robotic surgery with steep Trendelenburg position, maintenance of cardiac preload and cardiac output is important for clinical prognosis. Previous studies reported the positive end-expiratory pressure (PEEP)-induced increase in central venous pressure (CVP) could be a accurate predictor of fluid responsiveness in cardiac surgical patients. The authors attempt to evaluate the predictability of PEEP-induced increase in CVP as well as stroke volume variation in urologic robotic surgery with Steep Trendelenburg position.

Detailed Description

In urologic robotic surgery with steep Trendelenburg position, maintenance of cardiac preload and cardiac output is important for clinical prognosis. As a preload index, the predictability of central venous pressure, pulse pressure variation and stroke volume variations may be impaired due to the impaired hemodynamics that result from the effect of increased abdominal pressure and decreased venous return. Previous studies reported the positive end-expiratory pressure (PEEP)-induced increase in central venous pressure (CVP) could be a accurate predictor of fluid responsiveness in cardiac surgical patients. Therefore, the authors attempt to evaluate the predictability of PEEP-induced increase in CVP as well as stroke volume variation in urologic robotic surgery with Steep Trendelenburg position.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • Adult patient undergoing robot-assisted laparoscopic radical prostatectomy or cystectomy.
  • American Society of Anesthesiologist Physical Status Classification of 1, 2 or 3.
Exclusion Criteria
  • Medical history of arrhythmia or new-onset arrhythmia after anesthesia induction.
  • Valvular or ischemic heart disease or left ventricular ejection fraction less than 40%.
  • Any significant pulmonary disease or history of chronic obstructive pulmonary disease
  • End-stage renal disease or preoperative creatinine > 1.4 mg/dl

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Fluid responsiveness testFluid loading of volulyte 300 mlFirst, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation). Second, measure the increase in cardiac index after administration of volulyte 300 ml. If cardiac index increase more than 10%, fluid responsiveness is confirmed.
Primary Outcome Measures
NameTimeMethod
fluid responsiveness5 minutes after administration of 300 ml volulyte

fluid responsiveness is determined when increase in cardiac index is more than 10%

Secondary Outcome Measures
NameTimeMethod
arterial carbon dioxide partial pressure (mmHg)1 minutes after the start of skin closure

arterial blood gas analysis

central venous pressureT4: 5 minutes after administration of volulyte 300 ml

measurement of central venous pressure after fluid administration

cardiac indexT4: 5 minutes after administration of volulyte 300 ml

measurement of cardiac index after fluid administration

stroke volume variationT4: 5 minutes after administration of volulyte 300 ml

measurement of stroke volume variation after fluid administration

abdominal pressureT4: 5 minutes after administration of volulyte 300 ml

measurement of abdominal pressure after fluid administration

arterial oxygen partial pressure (mmHg)1 minutes after the start of skin closure

arterial blood gas analysis

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath